---
title: "ANKE BIO: The ORR of HuA21 injection combined with trastuzumab and chemotherapy for treating HER2-positive advanced gastric/gastroesophageal junction adenocarcinoma reached 80.8%"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/261950271.md"
description: "ANKE BIO presented research results on HuA21 injection combined with trastuzumab and chemotherapy for the treatment of HER2-positive advanced gastric/gastroesophageal junction adenocarcinoma at the 2025 European Society for Medical Oncology Annual Meeting. The study showed that the objective response rate in the HuA21 group was 80.8%, compared to 76.7% in the control group. A total of 60 patients were enrolled in the study, and the results indicated that HuA21 has good anti-tumor activity"
datetime: "2025-10-20T23:50:10.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/261950271.md)
  - [en](https://longbridge.com/en/news/261950271.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/261950271.md)
---

# ANKE BIO: The ORR of HuA21 injection combined with trastuzumab and chemotherapy for treating HER2-positive advanced gastric/gastroesophageal junction adenocarcinoma reached 80.8%

ANKE BIO announced that at the 2025 European Society for Medical Oncology Annual Meeting, the company presented the latest research results of its self-developed biological innovative drug HuA21 injection combined with trastuzumab and chemotherapy for the treatment of HER2-positive advanced gastric/gastroesophageal junction adenocarcinoma in the Ib/II phase dose escalation and expansion study. As of February 20, 2025, this study has enrolled 60 HER2-positive advanced gastric/gastroesophageal junction adenocarcinoma first-line patients. According to the assessment by an independent imaging evaluation committee, the objective response rate of the HuA21 group was 80.8%, while the objective response rate of the trastuzumab group was 76.7%, demonstrating good anti-tumor activity. There were no statistically significant differences in the demographic data and baseline characteristics between the two groups of patients

### Related Stocks

- [300009.CN](https://longbridge.com/en/quote/300009.CN.md)

## Related News & Research

- [Lytix Biopharma Advances Ruxotemitide Program as Q1 2026 Results Underscore Oncology Focus](https://longbridge.com/en/news/287162474.md)
- [15:55 ETInception Fertility Launches MySpermBank, Expanding Access to Donor Sperm Services Nationwide](https://longbridge.com/en/news/287265370.md)
- [New York Governor Signs Bills To Preserve Mandatory Vaccines](https://longbridge.com/en/news/286947583.md)
- [09:35 ETOpen Medicine Launches Ahead of ASCO, Introducing "Living Algorithms" for Real-Time Oncology Decision-Making](https://longbridge.com/en/news/286923155.md)
- [LG CNS Expands North American AX Business, Supporting Smart Factory Transformation for SMEs](https://longbridge.com/en/news/286971453.md)